Targeted Penetrating Motif Engineering of BH3 Mimetic: Harnessing Non‐Canonical Amino Acids for Coinhibition of MCL‐1 and BCL‐xL in Acute Myeloid Leukemia
Advanced Science · 2025
DOI: 10.1002/advs.202503682 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Science, 2025. Verfasst von Zhe Wang und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, The Eighth Affiliated Hospital, Sun Yat-sen University, Shenzhen, 518033, China. Hauptthemen laut MEDLINE: Leukemia, Myeloid, Acute, bcl-X Protein, Myeloid Cell Leukemia Sequence 1 Protein, Amino Acids. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 79 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Futian Healthcare Research Project, Guangdong Basic and Applied Basic Research Foundation, Shenzhen Science and Technology Program.
Abstract (Originalsprache)
Acute Myeloid Leukemia (AML) remains a formidable clinical challenge, predominantly due to the emergence of resistance to existing therapeutic regimens, including BCL‐2 inhibitors like Venetoclax. Here, a novel approach is introduced by engineering BH3 mimetics utilizing non‐canonical amino acids (ncAAs) to achieve dual inhibition of MCL‐1 and BCL‐xL. Through site saturation mutagenesis scanning, the I58(Chg) mutation is identified, significantly enhancing binding affinity with IC 50 values of 2.77 n m for MCL‐1 and 10.69 n m for BCL‐xL, reflecting an increase of fourfold or more. The developed vMIP‐II‐TAT‐I peptide, incorporating a CXCR4‐targeted penetrating motif, demonstrated superior cellular uptake, with mean fluorescence intensity (MFI) 7.2‐fold higher in CXCR4‐positive AML cells and exhibited a high selectivity index (SI) for AML cells, with minimal impact on normal human hematopoietic stem cells (HSCs). When combined with Venetoclax, this peptide induced synergistic apoptosis, reducing tumor burden and prolonging survival in an AML mouse model, with median survival extended to 53 days from 37 days with Venetoclax alone. These findings reveal the therapeutic potential of dual inhibition in overcoming Venetoclax resistance and selectively targeting leukemic cells with reduced off‐target effects, while laying the foundation for developing advanced BH3 mimetics with enhanced targeting, binding affinity, and efficacy for AML treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pathology, The Eighth Affiliated Hospital, Sun Yat-sen University, Shenzhen, 518033, China.
- School of Pharmaceutical Sciences, Shenzhen Campus of Sun Yat-sen University, Shenzhen, 518107, China.
ORCID-Profile: Junqing Wang
Förderung
- Futian Healthcare Research Project
- Guangdong Basic and Applied Basic Research Foundation
- Shenzhen Science and Technology Program
- Basic and Applied Basic Research Foundation of Guangdong Province
- Shenzhen Science and Technology Innovation Program
Zitieren
APA
Wang, Z., Lai, R., Wang, X., Chen, X., Zhou, Y., Li, S., Qiu, X., Zeng, Z., Yuan, J., Mao, J., Chen, Z., & Wang, J. (2025). Targeted Penetrating Motif Engineering of BH3 Mimetic: Harnessing Non‐Canonical Amino Acids for Coinhibition of MCL‐1 and BCL‐xL in Acute Myeloid Leukemia. Advanced Science. https://doi.org/10.1002/advs.202503682
Vancouver
Wang Z, Lai R, Wang X, Chen X, Zhou Y, Li S, et al. Targeted Penetrating Motif Engineering of BH3 Mimetic: Harnessing Non‐Canonical Amino Acids for Coinhibition of MCL‐1 and BCL‐xL in Acute Myeloid Leukemia. Advanced Science. 2025. doi:10.1002/advs.202503682
BibTeX
@article{Wang2025,
author = {Wang, Zhe and Lai, Ruizhi and Wang, Xinpei and Chen, Xu and Zhou, Youjian and Li, Shengbin and Qiu, Xiaohui and Zeng, Zekai and Yuan, Jianye and Mao, Jinghuan and Chen, Zhidong and Wang, Junqing},
title = {Targeted Penetrating Motif Engineering of BH3 Mimetic: Harnessing Non‐Canonical Amino Acids for Coinhibition of MCL‐1 and BCL‐xL in Acute Myeloid Leukemia},
journal = {Advanced Science},
year = {2025},
doi = {10.1002/advs.202503682}
}
EUVIMED